SEC Form 4 · accession 0001415889-19-000221
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert N Fried
Officer — CEO · Director
Period of report
Feb 21, 2019
Accepted (ET)
Feb 22, 2019 · 7:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (right to buy)F1 | $3.84 | Feb 21, 2019 | A | 162,569 | A | Feb 21, 2020 | Feb 21, 2029 | Common Stock | 162,569 | 162,569 | D |
Explanation of responses
- F1Options vest 33% on February 21, 2020 and thereafter 1/36th vest each month.